Research Articles

Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
stats4

Search for:

     Selonsertib
35 records.
Article ID PMID Source Title Publish Year
A01245 34815444 Sci Rep A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. 2021 Details
A01666 34662449 Hepatology Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. 2022 Details
A02701 34278169 Hepatol Commun Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. 2021 Details
A03067 34144391 Redox Biol Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules. 2021 Details
A03482 33987427 Ann Transl Med Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. 2021 Details
A04097 33761646 Medicine (Baltimore) The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. 2021 Details
A05080 33385317 J Dig Dis Efficacy and safety of drugs for nonalcoholic steatohepatitis. 2021 Details
A05119 33368954 Diabetes Obes Metab Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. 2021 Details
A05306 33307033 Gastroenterology The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. 2020 Details
A05376 33278029 Pharmacotherapy Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. 2021 Details
A05661 33169409 Hepatology Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. 2021 Details
A06102 33007418 Pharmacol Res Endoplasmic reticulum stress and protein degradation in chronic liver disease. 2020 Details
A06984 32673798 Mol Metab Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. 2020 Details
A07905 32316235 J Clin Med The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. 2020 Details
A08128 32237916 Expert Opin Pharmacother Current and new pharmacotherapy options for non-alcoholic steatohepatitis. 2020 Details
A08327 32151660 Metabolism Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. 2020 Details
A08342 32147362 J Hepatol Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. 2020 Details
A08711 32015483 Sci Rep Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. 2020 Details
A08933 31931543 Z Gastroenterol [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] 2020 Details
A10083 31495973 Hepatol Res Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. 2019 Details
A10613 31271665 Hepatology Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. 2019 Details
A11715 30779990 Clin Gastroenterol Hepatol Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. 2019 Details
A12023 30639779 Clin Gastroenterol Hepatol Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. 2019 Details
A12780 30291868 J Hepatol Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. 2018 Details
A12835 30261763 Expert Rev Gastroenterol Hepatol An update on the recent advances in antifibrotic therapy. 2018 Details
A13470 29956213 Adv Exp Med Biol Current Prevention and Treatment Options for NAFLD. 2018 Details
A14506 29377462 Liver Int Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. 2018 Details
A15013 29128056 Clin Liver Dis Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2017 Details
A15468 28892558 Hepatology The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. 2017 Details
A28744 35074532 Clin Gastroenterol Hepatol Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. 2022 Details
A31544 30315846 Cancer Lett Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. 2018 Details
A31571 30271738 J Clin Transl Hepatol Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. 2018 Details
A43821 30791762 Expert Rev Gastroenterol Hepatol Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease. 2019 Details
A51326 35601801 Therap Adv Gastroenterol Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. 2022 Details
A51441 35352662 Curr Top Med Chem Probing the interaction of Selonsertib with human serum albumin: In silico and in vitro approaches. 2022 Details